

DAFTAR PUSTAKA

1. Gennatas ED, Wu A, Braunstein SE, Morin O, Chen WC, Magill ST, et al. Preoperative and postoperative prediction of long-term meningioma outcomes. *PLOS ONE*. 2018 Sep 20;13(9):e0204161.
2. Ostrom QT, Cioffi G, Waite K, Kruchko C, Barnholtz-Sloan JS. CBTRUS Statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2014–2018. *Neuro Oncol*. 2021;23:iii1–105.
3. International Agency for Research on Cancer. World Health Organization. Indonesia Globocan 2020. The global cancer observatory. [cited 2021 Oct 11]. Available from: <http://gco.iarc.fr/today/data/factsheets/population/360-indonesia-fact-sheets.pdf>.
4. Rejeki DS, Agus S, Syafrita Y. Hubungan ekspresi reseptor progesteron dan Ki-67 labelling index dengan derajat histopatologik meningioma. *Maj Patol*. 2019;28(3):7.
5. Liu F, Qian J, Ma C. MPscore: a novel predictive and prognostic scoring for progressive meningioma. *Cancers*. 2021 Mar 5;13(5):1113.
6. Behling F, Fodi C, Hoffmann E, Renovanz M, Skardelly M, Tabatabai G, et al. The role of Simpson grading in meningiomas after integration of the updated WHO classification and adjuvant radiotherapy. *Neurosurg Rev*. 2021 Aug;44(4):2329–36.
7. Nowak A, Dziedzic T, Krych P, Czernicki T, Kunert P, Marchel A. Benign versus atypical meningiomas: risk factors predicting recurrence. *Neurol Neurochir Pol*. 2015 Jan;49(1):1–10.
8. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. Revised 4th edition. Lyon: International Agency for Research on Cancer; 2016. 408 p.
9. Corniola MV, Lemée J-M, Meling TR. Histological transformation in recurrent WHO grade I meningiomas. *Sci Rep*. 2020 Dec;10(1):11220.
10. Pettersson-Segerlind J, Orrego A, Lönn S, Mathiesen T. Long-term 25-year follow-up of surgically treated parasagittal meningiomas. *World Neurosurg*. 2011 Dec;76(6):564–71.
11. Gray F, Duyckaerts C, De Girolami U, Escourolle R, Gray F, editors. Escourolle & Poirier's manual of basic neuropathology. 5th ed. Oxford: Oxford University Press; 2014. 406 p.
12. Ellison D, editor. *Neuropathology: a reference text of CNS pathology*. 3. ed. Edinburgh: Mosby, Elsevier; 2013. 879 p.

13. Hess K, Spille DC, Adeli A, Sporns PB, Zitta K, Hummitzsch L, et al. Occurrence of fibrotic tumor vessels in grade I meningiomas is strongly associated with vessel density, expression of VEGF, PlGF, IGFBP-3 and tumor recurrence. *Cancers*. 2020 Oct 21;12(10):3075.
14. Barresi V, Cerasoli S, Vitarelli E, Tuccari G. Density of microvessels positive for CD105 (endoglin) is related to prognosis in meningiomas. *Acta Neuropathol (Berl)*. 2007 Jul 12;114(2):147–56.
15. Pistolesi S, Boldrini L, Gisfredi S, Ieso KD, Camacci T, Caniglia M, et al. Angiogenesis in intracranial meningiomas: immunohistochemical and molecular study: Angiogenesis in meningiomas. *Neuropathol Appl Neurobiol*. 2004 Apr;30(2):118–25.
16. Yamasaki F, Yoshioka H, Hama S, Sugiyama K, Arita K, Kurisu K. Recurrence of meningiomas: Influence of vascular endothelial growth factor expression. *Cancer*. 2000 Sep 1;89(5):1102–10.
17. Cross VL, Zheng Y, Won Choi N, Verbridge SS, Sutermaster BA, Bonassar LJ, et al. Dense type I collagen matrices that support cellular remodeling and microfabrication for studies of tumor angiogenesis and vasculogenesis in vitro. *Biomaterials*. 2010 Nov;31(33):8596–607.
18. Bordeleau F, Mason BN, Lollis EM, Mazzola M, Zanotelli MR, Somasegar S, et al. Matrix stiffening promotes a tumor vasculature phenotype. *Proc Natl Acad Sci*. 2017 Jan 17;114(3):492–7.
19. Sun X, Nkenkor B, Mastikhina O, Soon K, Nunes SS. Endothelium-mediated contributions to fibrosis. *Semin Cell Dev Biol*. 2020 May;101:78–86.
20. Willis MS, Yates CC, Schisler JC, editors. *Fibrosis in Disease: An Organ-Based Guide to Disease Pathophysiology and Therapeutic Considerations*. Cham: Springer International Publishing; 2019.
21. Hsu T, Nguyen-Tran H-H, Trojanowska M. Active roles of dysfunctional vascular endothelium in fibrosis and cancer. *J Biomed Sci*. 2019 Dec;26(1):86.
22. Strom A, Olin A, Aspberg A, Hultgardhnilsson A. Fibulin-2 is present in murine vascular lesions and is important for smooth muscle cell migration. *Cardiovasc Res*. 2006 Feb 15;69(3):755–63.
23. Sofela AA, Hilton DA, Ammoun S, Baiz D, Adams CL, Ercolano E, et al. Fibulin-2: a novel biomarker for differentiating grade II from grade I meningiomas. *Int J Mol Sci*. 2021 Jan 8;22(2):560.
24. Zhang H, Hui D, Fu X. Roles of fibulin-2 in carcinogenesis. *Med Sci Monit*. 2020 Jan 9;26.

25. Zhang X, Duan L, Zhang Y, Zhao H, Yang X, Zhang C. Correlation of Fibulin-2 expression with proliferation, migration and invasion of breast cancer cells. *Oncol Lett*. 2020 Jun 17;20(2):1945–51.
26. Tan H, Zhang J, Fu D, Zhu Y. Loss of fibulin-2 expression is involved in the inhibition of breast cancer invasion and forms a new barrier in addition to the basement membrane. *Oncol Lett*. 2017 Sep;14(3):2663–8.
27. Klingen TA, Chen Y, Aas H, Wik E, Akslen LA. Fibulin-2 expression associates with vascular invasion and patient survival in breast cancer. *PLOS ONE*. 2021 Apr 9;16(4):e0249767.
28. Schaeffer J, Tannahill D, Cioni J-M, Rowlands D, Keynes R. Identification of the extracellular matrix protein Fibulin-2 as a regulator of spinal nerve organization. *Dev Biol*. 2018 Oct;442(1):101–14.
29. Rauch U, Zhou X-H, Roos G. Extracellular matrix alterations in brains lacking four of its components. *Biochem Biophys Res Commun*. 2005 Mar;328(2):608–17.
30. Anthony T. Yachnis MD, Marie L Rivera-Zengotita MD. *Neuropathology: A Volume in the High Yield Pathology Series*. Saunders; 2013. 136p.
31. Prayson RA, Cohen ML. *Practical differential diagnosis in surgical neuropathology*. Totowa, N.J: Humana Press; 2000. 179 p.
32. Rockhill J, Mrugala M, Chamberlain MC. Intracranial meningiomas: an overview of diagnosis and treatment. *Neurosurg Focus*. 2007 Oct;23(4):E1.
33. Rogers L, Barani I, Chamberlain M, Kaley TJ, McDermott M, Raizer J, et al. Meningiomas: knowledge base, treatment outcomes, and uncertainties. *J Neurosurg*. 2015 Jan;122(1):4–23.
34. Anne G. Osborn, Gary L. Hedlund, Karen L. Salzman. *Osborn's Brain: imaging, pathology, and anatomy*. Elsevier. 2018. 659p.
35. Kleinschmidt-DeMasters BK, Rodríguez FJ, Tihan T, Burger PC, Scheithauer BW, Ersen A, et al., editors. *Diagnostic pathology: neuropathology*. Second edition. Philadelphia, PA: Elsevier; 2016. 805 p.
36. Kementerian Kesehatan Republik Indonesia. *Pedoman Nasional Pelayanan Kedokteran Tumor Otak*. Komite Penanggulangan Kanker Nasional. [cited 2021 August 29]. Available from: <http://kanker.kemkes.go.id/guidelines/PNPKOtak.pdf>.
37. Claus EB, Bondy ML, Schildkraut JM, Wiemels JL, Wrensch M, Black PM. Epidemiology of Intracranial Meningioma: *Neurosurgery*. 2005 Dec;57(6):1088–95.

38. Wiemels J, Wrensch M, Claus EB. Epidemiology and etiology of meningioma. *J Neurooncol*. 2010 Sep;99(3):307–14.
39. Choy W, Kim W, Nagasawa D, Stramotas S, Yew A, Gopen Q, et al. The molecular genetics and tumor pathogenesis of meningiomas and the future directions of meningioma treatments. *Neurosurg Focus*. 2011 May;30(5):E6.
40. Perry A, Gutmann DH, Reifenberger G. Molecular pathogenesis of meningiomas. *J Neurooncol*. 2004 Nov;70(2):183–202.
41. Perry A, Brat DJ, editors. *Practical surgical neuropathology: a diagnostic approach*. Philadelphia, PA: Churchill Livingstone/Elsevier; 2010. 620 p.
42. Al-Hadidy AM, Maani WS, Mahafza WS, Al-Najar MS, Al-Nadii MM. Intracranial Meningioma. *DAR Publ*. 2007;41(1):37–51.
43. Tonn JC, Westphal M, Rutka JT, Grossman SA. eds. *Neuro-Oncology of CNS Tumors*. 2006. Springer. 82-99p.
44. Buerki RA, Horbinski CM, Kruser T, Horowitz PM, James CD, Lukas RV. An overview of meningiomas. *Future Oncol*. 2018 Sep;14(21):2161–77.
45. Riemenschneider MJ, Perry A, Reifenberger G. Histological classification and molecular genetics of meningiomas. *Lancet Neurol*. 2006 Dec;5(12):1045–54.
46. Bi WL, Zhang M, Wu WW, Mei Y, Dunn IF. Meningioma genomics: diagnostic, prognostic, and therapeutic applications. *Front Surg*. 2016 Jul 6;3.
47. Esiri MM, Perl DP, Oppenheimer DR. *Oppenheimer's diagnostic neuropathology: a practical manual*. 3rd ed. London: New York: Hodder Arnold; Distributed in the United States of America by Oxford University Press; 2006. 566 p.
48. Love S, Perry A, Ironside J, Budka H. *Greenfield's Neuropathology*. Ninth Ed. CRC Press; 2015. 1803 p.
49. Di Carlo SE, Peduto L. The perivascular origin of pathological fibroblasts. *J Clin Invest*. 2018 Jan 2;128(1):54–63.
50. Peleli M, Moustakas A, Papapetropoulos A. Endothelial-tumor cell interaction in brain and CNS malignancies. *Int J Mol Sci*. 2020 Oct 6;21(19):7371.
51. Davis GE, Senger DR. Endothelial extracellular matrix: biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. *Circ Res*. 2005 Nov 25;97(11):1093–107.

52. Wynn TA. Cellular and molecular mechanisms of fibrosis. *J Pathol.* 2008 Jan;214(2):199-210.
53. Brigstock DR. Extracellular vesicles in organ fibrosis: mechanisms, therapies, and diagnostics. *Cells.* 2021 Jun 25;10(7):1596.
54. Darwin E, Elfi EF, Elvira D. Endotel: Fungsi dan disfungsi. I. Andalas University Press; 2017. 186 p.
55. Harvey A, Montezano AC, Lopes RA, Rios F, Touyz RM. Vascular fibrosis in aging and hypertension: molecular mechanisms and clinical implications. *Can J Cardiol.* 2016 May;32(5):659–68.
56. Andrews RN, Metheny-Barlow LJ, Peiffer AM, Hanbury DB, Tooze JA, Bourland JD, et al. Cerebrovascular remodeling and neuroinflammation is a late effect of radiation-induced brain injury in non-human primates. *Radiat Res.* 2017 May;187(5):599–611.
57. Andrews RN, Caudell DL, Metheny-Barlow LJ, Peiffer AM, Tooze JA, Bourland JD, et al. Fibronectin produced by cerebral endothelial and vascular smooth muscle cells contributes to perivascular extracellular matrix in late-delayed radiation-induced brain injury. *Radiat Res.* 2018 Jul 22;190(4):361.
58. Percival KR, Radi ZA. A modified Verhoeff's elastin histochemical stain to enable pulmonary arterial hypertension model characterization. *Eur J Histochem.* 2016 Feb 11;60(1).
59. Suvarna KS, Layton C, Bancroft JD. Bancroft's Theory and Practice of Histological Techniques. Eight ed. United Kingdom: Elsevier; 2019. 165p.
60. Cangemi C, Hansen ML, Argraves WS, Rasmussen LM. Fibulins and their role in cardiovascular biology and disease. In: *Advances in Clinical Chemistry.* Elsevier; 2014. p. 245–65.
61. Tsuda T. Extracellular interactions between Fibulins and Transforming Growth Factor (TGF)- β in physiological and pathological conditions. *Int J Mol Sci.* 2018 Sep 17;19(9):2787.
62. Ibrahim AM, Sabet S, El-Ghor AA, Kamel N, Anis SE, Morris JS, et al. Fibulin-2 is required for basement membrane integrity of mammary epithelium. *Sci Rep.* 2018 Dec;8(1):14139.
63. Longmate WM, Monichan R, Chu M-L, Tsuda T, Mahoney MG, DiPersio CM. Reduced Fibulin-2 contributes to loss of basement membrane integrity and skin blistering in mice lacking integrin $\alpha 3\beta 1$ in the epidermis. *J Invest Dermatol.* 2014 Jun;134(6):1609–17.

64. Law EWL, Cheung AKL, Kashuba VI, Pavlova TV, Zabarovsky ER, Lung HL, et al. Anti-angiogenic and tumor-suppressive roles of candidate tumor-suppressor gene, Fibulin-2, in nasopharyngeal carcinoma. *Oncogene*. 2012 Feb;31(6):728–38.
65. Pearce D. Investigation of fibulin-2 in pulmonary fibrosis [Internet]. University College London; 2021 [cited 2022 Feb 1]. Available from: <https://discovery.ucl.ac.uk/id/eprint/10133999/>
66. Argraves WS, Greene LM, Cooley MA, Gallagher WM. Fibulins: physiological and disease perspectives. *EMBO Rep*. 2003 Dec;4(12):1127–31.
67. Ramaswamy S, Ross KN, Lander ES, Golub TR. A molecular signature of metastasis in primary solid tumors. *Nat Genet*. 2003 Jan;33(1):49–54.
68. Fontanil T, Mohamedi Y, Cobo T, Cal S, Obaya ÁJ. Novel associations within the tumor microenvironment: Fibulins meet ADAMTSs. *Front Oncol*. 2019 Aug 22;9:796.
69. Senapati S, Gnanapragassam VS, Moniaux N, Momi N, Batra SK. Role of MUC4–NIDO domain in the MUC4-mediated metastasis of pancreatic cancer cells. *Oncogene*. 2012 Jul;31(28):3346–56.
70. Yi C-H, Smith DJ, West WW, Hollingsworth MA. Loss of Fibulin-2 expression is associated with breast cancer progression. *Am J Pathol*. 2007 May;170(5):1535–45.
71. Mahajan D, Kancharla S, Kolli P, Sharma AK, Singh S, Kumar S, et al. Role of Fibulins in embryonic stage development and their involvement in various diseases. *Biomolecules*. 2021 May 2;11(5):685.
72. Radice PD, Mathieu P, Leal MC, Farías MI, Ferrari C, Puntel M, et al. Fibulin-2 is a key mediator of the pro-neurogenic effect of TGF-beta1 on adult neural stem cells. *Mol Cell Neurosci*. 2015 Jul;67:75–83.
73. Zhang H, Wu J, Dong H, Khan SA, Chu M-L, Tsuda T. Fibulin-2 deficiency attenuates angiotensin II-induced cardiac hypertrophy by reducing transforming growth factor- β signalling. *Clin Sci*. 2014 Feb 1;126(4):275–88.
74. Tsuda T, Wu J, Gao E, Joyce J, Markova D, Dong H, et al. Loss of fibulin-2 protects against progressive ventricular dysfunction after myocardial infarction. *J Mol Cell Cardiol*. 2012 Jan;52(1):273–82.
75. Khan SA, Dong H, Joyce J, Sasaki T, Chu M-L, Tsuda T. Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)- β . *Lab Invest*. 2016 Jul;96(7):773–83.

76. Sastroasmoro S, Ismael S. Dasar-dasar Metodologi Penelitian Klinis. Edisi ke-4. Sagung Seto. 2011;527.
77. Lakshmi SS. Meningiomas: A Clinicopathological study. *Int J Med Res Health Sci.* 2015;4(4):827.
78. Li W-M, Chan T-C, Huang SK-H, Wu W-J, Ke H-L, Liang P-I, et al. Prognostic Utility of FBLN2 Expression in Patients With Urothelial Carcinoma. *Front Oncol.* 2020 Oct 29;10:570340.
79. Karim AKMB, Joarder MA, Islam S, Akhter N, Orin M, Hossain J, Khaled A, et al. Clinical profile and outcome of intracranial meningioma in Apollo Hospital Dakha. *Pulse Vol 9.* 2016: p.22-7.
80. Mariana A, Delyuzar, Alferraly TI. Hubungan Ekspresi Fibroblast Growth Factor-2 (FGF-2) dengan Grade Histopatologi Meningioma. 2019.
81. Korhonen K, Raitanen J, Isola J, Haapasalo H, Salminen T, Auvinen A. Exogenous sex hormone use and risk of meningioma: a population-based case-control study in Finland. *Cancer Causes Control.* 2010 Dec;21(12):2149-56.
82. Hsu DW, Efir JT, Hedley-Whyte ET. Progesterone and estrogen receptors in meningiomas: prognostic considerations. *J Neurosurg.* 1997 Jan;86(1):113-20.
83. Samadi N, Ahmadi SA. Meningioma: a clinicopathological evaluation. *Malaysian Journal of Medical Sciences.* 2007 Jan; 14(1):p. 46-52.I.
84. Ros-Sanjuan A, Iglesias-Moroño S, Carrasco-Brenes A, Bautista-Ojeda D, Arraez-Sanchez MA. Atypical Meningiomas: Histologic and Clinical Factors Associated With Recurrence. *World Neurosurg.* 2019 May;125:e248-56.
85. Malik V, Punia R, Malhotra A, Gupta V. Clinicopathological Study Of Meningioma: 10 Year Experience From a Tertiary Care Hospital. *Glob J Res Anal.* 2018 Jan;7(1):3.
86. Desai P, Patel D. Histopathological study of meningioma. *Int J Med Sci Public Health.* 2016;5(2):327.
87. Jansari DrT, Patel DrJP, Chaudhari DrVV. Clinicopathological study of Meningioma. *Trop J Pathol Microbiol.* 2020 Jan 14;6(1):10-7.